Skip to content
ClinCalc Pro
Menu
First-Generation Cephalosporin Pregnancy: Animal studies do not indicate direct or indirect harmful effects on reproductive toxicity, but cefazolin crosses the placenta and there is insufficient experience; it should only be administered in pregnancy, especially during the first trimester, after careful benefit-risk assessment, and it is preferable to avoid use during pregnancy unless absolutely necessary. Cefazolin is excreted in maternal milk at very low concentrations and should only be used after careful benefit/risk assessment; if diarrhoea or candidiasis occurs in the infant, breastfeeding or treatment should be stopped (SPC section 4.6).

Cefazolin (Perioperative Burns)

Brand names: Kefzol

Cefazolin is a first-generation intravenous cephalosporin used for surgical antibiotic prophylaxis around burns operations such as excision and grafting.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Perioperative prophylaxis: 1 g cefazolin 30 to 60 minutes before surgery; in case of long surgical procedures (2 hours or more), an additional 0.5 to 1 g cefazolin during the intervention
Route: Slow intravenous injection or intravenous infusion after dilution; single doses exceeding 1 g should be given as intravenous infusion. If lidocaine is used as a solvent (for intramuscular use), the resulting solution must NEVER be administered intravenously
Frequency: Single pre-operative dose 30 to 60 minutes before the start of surgery, with intra-operative re-dosing (0.5 to 1 g) for procedures lasting 2 hours or more; prolonged continuation of administration beyond the surgical intervention should be supported by national official guidance
Max: No maximum is stated for perioperative prophylaxis. For treatment of infection the SPC states that in severe infections doses up to 6 g cefazolin per day can be administered in three or four equal doses (one dose every 6 to 8 hours)
SOURCE: UK SPC (eMC) for Cefazolin 2g Powder for solution for infusion/injection vials, section 4.2 (https://www.medicines.org.uk/emc/product/102464/smpc). The prophylaxis regimen above is quoted from the SPC's own 'Special dosage recommendations - Perioperative prophylaxis' subsection for the prevention of postoperative infection in contaminated or potentially contaminated surgery. The SPC contains NO burns-specific regimen: burns, burn-excision surgery and grafting are not named anywhere in the fetched sections, so the timing and re-dosing above are the general surgical-prophylaxis figures and any burns-unit-specific protocol (e.g. re-dosing for large blood loss or altered clearance in major burns) must come from local guidance. SPC rationale for the timing: the preoperative dose must be given just (30 minutes to 1 hour) prior to the start of surgery so that adequate antibiotic levels are present in the serum and tissues at the time of initial surgical incision, and cefazolin should be administered, if necessary, at appropriate intervals during surgery to provide sufficient levels at the anticipated moments of greatest exposure to infective organisms. TREATMENT DOSES (for context, not for prophylaxis) - adults and adolescents above 12 years and 40 kg or more: infections caused by sensitive microorganisms 1 g to 2 g per day divided into 2-3 equal doses; moderately sensitive microorganisms 3 g to 4 g per day divided into 3-4 equal doses; severe infections up to 6 g per day in three or four equal doses. Duration of treatment depends on the severity of the infection and on clinical and bacteriological progress. Elderly: no dose adjustment is required in elderly patients with normal renal function. US CROSS-CHECK (openFDA, Cefazolin for Injection, WG Critical Care - US labelling, differs from the UK SPC and is NOT the regimen above): 1 gram IV or IM half an hour to 1 hour before surgery; 500 mg to 1 gram IV or IM during surgery for lengthy procedures (e.g. 2 hours or more); and 500 mg to 1 gram IV or IM every 6 to 8 hours for 24 hours postoperatively, continued for 3 to 5 days after surgery where infection would be particularly devastating (e.g. open-heart surgery and prosthetic arthroplasty). The UK SPC defers postoperative continuation to national official guidance instead. PAEDIATRIC: this SPC gives NO paediatric perioperative prophylaxis dose - its paediatric figures are per-kg daily doses for the treatment of infection (divided into 2 to 4 doses per day) and must not be carried onto this perioperative page; the numbers are therefore not reproduced here. Use of cefazolin is not recommended in premature babies and infants below the age of 1 month, as safety has not been established. Verify all paediatric dosing against a children's formulary. Section 4.5 (interactions) was not retrieved in this bundle - the interaction entries below come from the SPC's section 4.4 and from US labelling, and the full section 4.5 should be verified.

Dose adjustments

Renal

Adults with renal impairment may need a lower dose; this lower dose may be guided by determining blood levels, or if that is not possible the dosage can be established from creatinine clearance. SPC maintenance schedule: creatinine clearance 55 mL/min or more (serum creatinine 1.5 mg/100 mL or less) - normal dose and normal dosing interval; 35-54 mL/min (1.6-3.0 mg/100 mL) - normal dose every 8 hours; 11-34 mL/min (3.1-4.5 mg/100 mL) - half of the normal dose every 12 hours; 10 mL/min or less (4.6 mg/100 mL or more) - half of the normal dose every 18-24 hours. In haemodialysis patients the treatment schedule depends on the dialysis conditions. Although cefazolin rarely causes renal dysfunction, renal function should be monitored, especially in severely ill patients receiving maximum doses and in patients receiving other potentially nephrotoxic agents.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance
  • History of severe hypersensitivity (e.g. anaphylactic reaction) to other beta-lactam antibiotics (penicillins, monobactams and carbapenems)
  • Contraindications to lidocaine must be excluded before intramuscular injection of cefazolin when lidocaine solution is used as a solvent; cefazolin solutions containing lidocaine must never be administered intravenously

Side effects

  • Common: oral candidiasis; genital candidiasis and vaginitis
  • Gastrointestinal: nausea, vomiting, diarrhoea, anorexia; pseudomembranous colitis, which can be life-threatening and requires immediate cessation of cefazolin and appropriate therapy
  • Hypersensitivity: rash, erythema, erythema multiforme, urticaria, angioedema; anaphylactic shock; rarely toxic epidermal necrolysis and Stevens-Johnson syndrome; Kounis syndrome (allergic coronary vasospasm potentially leading to myocardial infarction) has been reported
  • Blood: leukopenia, granulocytopenia, neutropenia, thrombocytopenia, eosinophilia and other count changes - rare and reversible; coagulation disorders with subsequent bleeding
  • Hepatobiliary: transient elevation of AST, ALT, alkaline phosphatase, gamma-GT, bilirubin and/or LDH; transient hepatitis and transient cholestatic jaundice
  • Renal: nephrotoxicity, interstitial nephritis, proteinuria and transient elevation of blood urea nitrogen, usually in patients concomitantly treated with other potentially nephrotoxic agents; seizures have occurred in patients with renal dysfunction treated with inappropriately high doses

Interactions

  • Section 4.5 of the UK SPC was not retrieved in this bundle - verify the full interaction section
  • Potentially nephrotoxic agents such as aminoglycosides or potent diuretics (e.g. furosemide) given concomitantly - monitor renal function, especially in severely ill patients receiving maximum doses (SPC section 4.4)
  • Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels (US labelling)
  • Laboratory tests: a false positive reaction for glucose in the urine may occur with Benedict's solution, Fehling's solution or CLINITEST tablets, but not with enzyme-based tests; positive direct and indirect antiglobulin (Coombs) tests have occurred, including in neonates whose mothers received cephalosporins before delivery (US labelling)
  • Antiperistaltic agents are contraindicated if antibiotic-associated pseudomembranous colitis is suspected (SPC section 4.4)

Clinical monograph

How it works

It binds penicillin-binding proteins to inhibit bacterial cell-wall peptidoglycan synthesis, giving reliable activity against staphylococci and streptococci that cause surgical-site infection.

Prescribing in practice

  • Avoid in patients with a history of severe or immediate hypersensitivity to penicillins or cephalosporins, and use caution with any prior beta-lactam allergy.
  • For prophylaxis it should be given so that adequate tissue concentrations are present at incision, with intra-operative re-dosing for prolonged procedures or major blood loss.
  • Burns patients have altered, often increased, drug clearance and a large volume of distribution, so standard prophylactic exposure may be inadequate.

Monitoring

Monitor for hypersensitivity reactions and for surgical-site infection in the postoperative period.

Counselling the patient

  • This antibiotic is given to lower the chance of wound infection around your operation.
  • Tell the team about any previous reaction to penicillin or cephalosporin antibiotics.

Evidence & guidelines

Cefazolin is a guideline-recommended agent for surgical prophylaxis against skin-flora organisms across many procedure types.

Reference: NICE NG125; ASHP antimicrobial prophylaxis guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.